Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) EBT (2016 - 2025)

Historic EBT for Niagen Bioscience (NAGE) over the last 17 years, with Q3 2025 value amounting to $4.8 million.

  • Niagen Bioscience's EBT rose 15559.11% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.3 million, marking a year-over-year increase of 133111.11%. This contributed to the annual value of $8.9 million for FY2024, which is 27932.36% up from last year.
  • Per Niagen Bioscience's latest filing, its EBT stood at $4.8 million for Q3 2025, which was up 15559.11% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's EBT ranged from a high of $7.5 million in Q4 2024 and a low of -$8.9 million during Q3 2021
  • In the last 5 years, Niagen Bioscience's EBT had a median value of -$1.4 million in 2022 and averaged -$1.5 million.
  • In the last 5 years, Niagen Bioscience's EBT crashed by 11010.68% in 2021 and then soared by 2501333.33% in 2025.
  • Niagen Bioscience's EBT (Quarter) stood at -$5.3 million in 2021, then soared by 72.88% to -$1.4 million in 2022, then soared by 107.89% to $114000.0 in 2023, then skyrocketed by 6464.91% to $7.5 million in 2024, then plummeted by 35.86% to $4.8 million in 2025.
  • Its EBT was $4.8 million in Q3 2025, compared to $3.7 million in Q2 2025 and $5.2 million in Q1 2025.